Overview

Clinical Trial Evaluating Gastrointestinal Damage Following Administration PL3100 or Naproxen in At-Risk Adults

Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to determine the subchronic gastrointestinal (GI) safety of PL3100 versus Naproxen in normal healthy volunteers.
Phase:
Phase 2
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
PLx Pharma
Collaborator:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Treatments:
Naproxen
Criteria
Inclusion Criteria (Selected)

- Male and female healthy adult subjects

Exclusion Criteria (Selected)

- Subject has protocol specified significant medical history.

- Subject is currently participating, or has participated within 30 days prior to study
entry, in an investigational drug study.

- Subject has hypersensitivity or contraindications to naproxen, ibuprofen, or other
NSAID.